ReviewGene therapy2006
Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders.
Review in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 115 citations in OpenAlex.
- Review
- Ophthalmic Administration of a DNA Plasmid Harboring the Murine Tph2 Gene: Evidence of Recombinant Tph2-FLAG in Brain Structures.Molecular biotechnology · 2020Article
- A method for gene knockdown in the retina using a lipid-based carrier.Molecular vision · 2020Article
- Lipopeptide Delivery of siRNA to the Central Nervous System.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Corneal chemical burn treatment through a delivery system consisting of TGF-βDrug delivery and translational research · 2018Article
- Gene delivery nanoparticles to modulate angiogenesis.Advanced drug delivery reviews · 2017Review
- The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.Pharmaceutical research · 2017Review
- An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment.Parasite (Paris, France) · 2015Review
- Therapeutic potential of siRNA and DNAzymes in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Molecular umbrella conjugate for the ocular delivery of siRNA.Bioconjugate chemistry · 2014Article
- In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Delivery systems and local administration routes for therapeutic siRNA.Pharmaceutical research · 2013Review
- Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.Antimicrobial agents and chemotherapy · 2013Article
- RNA Interference Targeting Connective Tissue Growth Factor Inhibits the Transforming Growth Factor- β 2 Induced Proliferation in Human Tenon Capsule Fibroblasts.Journal of ophthalmology · 2013Article
- Lipopeptide delivery of siRNA to the central nervous system.Methods in molecular biology (Clifton, N.J.) · 2013Article
- mRNA knockdown by single strand RNA is improved by chemical modifications.Nucleic acids research · 2012Article
- Progress toward in vivo use of siRNAs-II.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
- Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits.British journal of pharmacology · 2012Article
- siRNA-optimized Modifications for Enhanced In Vivo Activity.Molecular therapy. Nucleic acids · 2012Article
- Emerging techniques to treat corneal neovascularisation.Eye (London, England) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eye is a relatively isolated tissue compartment, which provides advantages for utilization of small interfering RNA (siRNA). Feasibility of using siRNA for treatment of choroidal neovascularization has been demonstrated using siRNA directed against vascular endothelial growth factor (VEGF) or VEGF receptor 1 (VEGFR1), and both of these approaches are being tested in clinical trials. The results with VEGFR1 siRNA show that VEGFR1 is pro-angiogenic in the eye and is not a decoy receptor as it is in developmental angiogenesis. Topical delivery of siRNAs directed against VEGF or its receptors has also been shown to suppress corneal neovascularization. Signaling through transforming growth factor-beta receptor 2 (TGFbetaR2) has been implicated in excessive ocular scarring and TGFbetaR2 siRNA has shown benefit in a model relevant to excessive scarring after glaucoma filtration surgery. RNAi has been used to identify genes that promote apoptosis or oxidative damage in retinal cells and could be the basis of new treatments for glaucoma or photoreceptor degenerations. In cultured cells derived from ocular tissues, siRNA has become a valuable tool to explore the potential role of various genes in ocular disease processes. Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.